NCT04059978View on ClinicalTrials.gov

Pain Response to Cannabidiol in Opioid-induced Hyperalgesia, Acute Nociceptive Pain and Allodynia By Using a Model Mimicking Acute Pain in Healthy Adults

NACompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 26, 2020

Primary Completion Date

October 15, 2020

Study Completion Date

October 15, 2020

Conditions
Acute Nociceptive PainHyperalgesiaAllodyniaOpioid-induced Hyperalgesia
Interventions
DRUG

CBD

1600mg cannabidiol, single oral dose (8 ml oily solution)

DRUG

Placebo

Placebo p.o, single oral dose (8 ml oily solution)

DRUG

Remifentanil

Remifentanil 0.1 µg/kg/min i.v. for 30 min

Trial Locations (1)

4031

Department of Anaesthesiology, University Hospital of Basel (USB), Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT04059978 - Pain Response to Cannabidiol in Opioid-induced Hyperalgesia, Acute Nociceptive Pain and Allodynia By Using a Model Mimicking Acute Pain in Healthy Adults | Biotech Hunter | Biotech Hunter